Key Findings
The North America market for the stem cell assay market is anticipated to grow $xx million by 2027 from $xx million in 2018. During the forecast period, the growth of the market is presumed at CAGR of 17.87%.

Rise in the adoption of stem cell assay, the evolvement of technology and increase spending in the stem cell assay market are the key drivers in the North America stem cell assay market.

Market Insights
The North America stem cell assay market is segmented on the basis of types of assay, product, kits, application, end-user, and geography. The North America stem cell assay market by type is segmented into cell viability and toxicity assays, isolation and purification assays, cell identification assays, cell differentiation assays, cell function assays, and cell apoptosis assays. The product of North America stem cell assay market is segmented into instruments and detection kits. The kits of stem cell assay market are further segmented into adult stem cell kits, human embryonic stem cell kit. The stem cell market by application is further bifurcated into regenerative medicine and therapy development, drug discovery and development and clinical research market. The end-user of the stem cell market is segmented into research institutes and industry research. The North America stem cell assay market by geography is segmented into the US and Canada.

Increasing adoption of stem cell assay, improvement in the technology, high expense in stem cell research are the major drivers for the market growth in the North America region. The rise in the adoption of stem cell assay for drug screening & testing is one of the major reasons driving industry research.

Competitive Insights
The major companies that are mentioned in stem cell assay market of North America are Bio-Rad, Hemogenix Inc., Corning Inc., Stryker Corporation, R&D Systems, Merck Millipore (holding company is Merck KGaA), Fibrocell Science Inc., Thermo Fisher, GE Healthcare, Becton Dickinson, Promega Corporation, Takara Holdings Inc., Cellular Dynamics International (Holding Company Fujifilm), Stem Cell Technologies and Cell Bio Labs, Inc.